The malaria vaccine question in Africa is no longer scientific — it's who pays

For two decades the central obstacle to a malaria vaccine was the science. A new analysis in Archives of Public Health argues that obstacle has now been cleared, and a different one has taken its place: money. The World Health Organization endorsed the RTS,S/AS01 vaccine in October 2021 and the R21/Matrix-M vaccine in October 2023 [s1]. "The central question confronting African policymakers, donors, and governments is no longer scientific but financial," the authors write [s1].

The burden the vaccines are meant to blunt

The scale sets the stakes. In 2024, an estimated 282 million malaria cases and 610,000 deaths occurred worldwide, with the African region accounting for more than 94% of cases and 95% of deaths [s1]. WHO's own malaria fact sheet puts the same year at 282 million cases and 610,000 deaths across 80 countries, and attributes 95% of cases — 265 million — and 95% of deaths — 579,000 — to the African Region, where children under 5 accounted for about 75% of all malaria deaths [s3]. The disease remains, in the analysis's framing, one of the most persistent infectious threats in sub-Saharan Africa, concentrated among children under five [s1].

Why the financing is the hard part

Gavi, the Vaccine Alliance, has committed to introducing malaria vaccines through its advance market commitment model [s1]. But the analysis argues the alliance's tiered co-financing framework places a fiscal burden on exactly the countries least able to carry it — the highest-burden, lowest-income states [s1]. The authors invoke the COVID-19 pandemic as a cautionary case, noting how vaccine nationalism and concentrated manufacturing delayed equitable access to Africa the last time a new shot was scarce [s1].

Procurement is also only part of the bill. Effective delivery requires sustained investment in cold-chain systems, the health workforce, and immunisation platforms that can reach conflict-affected areas — costs the authors say are frequently excluded from procurement estimates [s1]. And the domestic side of the ledger is thin: most African Union member states remain below the Abuja Declaration target of allocating 15% of national spending to health, which the analysis says sustains dependence on external financing and undermines health sovereignty [s1]. Its prescription is coordinated action across donors, governments and manufacturers, including predictable multi-year financing and differential pricing [s1].

What rollout looks like where it has started

A separate systematic review in the American Journal of Tropical Medicine and Hygiene offers a ground-level view from Nigeria, where malaria remains a leading cause of illness and death among children under 5 [s2]. Screening literature from 2015 to 2026, the authors identified 12 eligible studies and found that demand, at least among caregivers, is not the bottleneck [s2]. Caregiver acceptance of the vaccine ranged from 76.6% in Lagos to 95.6% in Owerri, exceeding 90% in Enugu, Ondo State and Gombe [s2].

Awareness, however, lagged behind acceptance — ranging from 9.7% in Lagos to 72.1% in Enugu — and knowledge among the health workers expected to deliver the shots was uneven [s2]. Physicians showed higher adequate knowledge (68.9%) than nurses (35.9%), and 55.5% of nurses had only heard of the vaccine [s2]. Among pharmacists, just 54.1% were willing to vaccinate their own children, with concerns clustering around vaccine failure (53.6%), adverse effects (63.4%) and storage conditions (77.8%) [s2].

The willingness-to-pay figures underline the financing argument. Median willingness to pay in Enugu was USD $0.82 per dose, 71.2% of Lagos caregivers expressed willingness to pay something, and 90% of respondents nationally preferred government-funded vaccination [s2]. In other words, families want the vaccine but expect the state to fund it — the same fiscal gap the Archives analysis describes.

The readiness gap

Where the Nigerian review is bluntest is on the systems meant to carry the vaccine the last mile. Overall facility preparedness scores ranged from 33% to 51%, which the authors call critically inadequate [s2]. Advocacy and social mobilisation stood at 0% across all three facilities assessed for that indicator, and monitoring and supervision ranged from 0% to 33% [s2]. These are precisely the delivery costs the financing analysis warns are left out of headline procurement figures [s1].

What to watch

Neither paper claims the vaccines do not work; both take their efficacy as established and turn to the machinery around them. The open questions are whether Gavi's co-financing terms can be made to fit the budgets of the countries carrying most of the burden, whether domestic health spending moves toward the Abuja target rather than away from it, and whether delivery investment — cold chain, trained workers, supervision — is funded alongside the doses rather than assumed [s1]. On current figures, demand for the shots in high-burden settings appears to be running ahead of the systems and financing meant to deliver them [s2].

Sources

• Who will pay for the malaria vaccines in Africa?, Archives of Public Health, 21 July 2026
• Malaria Vaccine Rollout in Nigeria: Current Status and Challenges, American Journal of Tropical Medicine and Hygiene, 27 August 2026
• Malaria — fact sheet, World Health Organization, 4 December 2025